Rosiglitazone metformin adduct inhibits hepatocellular carcinoma proliferation via activation of AMPK/p21 pathway
Open Access
- 11 January 2019
- journal article
- research article
- Published by Springer Nature in Cancer Cell International
- Vol. 19 (1) , 13
Abstract
Rosiglitazone metformin adduct (RZM) is a novel compound, synthesized from rosiglitazone (Ros) and metformin (Met) combined at a molar mass ratio of 1:1. Met and Ros are widely used together for treating type 2 diabetes to improve drug effectiveness and reduce adverse drug reactions. Recent studies reported that both Met and Ros may possess antineoplastic properties in several cancers, including hepatocellular carcinoma (HCC). However, the effects of RZM in HCC and its underlying mechanisms remain unknown. RZM was synthesized from Ros and Met at an equal molar ratio and identified by infrared spectroscopy. MTS and colony formation assays were performed to detect proliferative repression of RZM, the mixture, Met and Ros, respectively. Tumorigenesis assay in vivo was used to confirm the anti-tumorigenesis potential of RZM and Met. Moreover, cellular apoptosis caused by RZM was analyzed by hoechst staining assay and flow cytometry. RT-qPCR and western blotting were performed to reveal mechanisms for the function of RZM. Both in vitro and in vivo data showed that low doses of RZM enhanced inhibitory effect on HCC cells growth compared with Met. Flow cytometry analysis confirmed that treatment with RZM at 1 mM for 48 h triggered HCC cells apoptosis. RT-qPCR and western blotting analyses showed that p21 was upregulated in response to 1 mM RZM treatment. Furthermore, RZM could increase AMPK activation compared with Met. The increased p21 expression induced by RZM treatment was attenuated by an AMPK inhibitor compound C. All these observations demonstrate that RZM increases the antiproliferative effect of Met in HCC via upregulating p21 expression in an AMPK-dependent manner. Our results suggest that RZM has the potential to be an adjuvant for HCC therapy.Keywords
Funding Information
- the Basic research and frontier exploration project of Yuzhong District of Chongqing (20180109)
- the Natural Science Foundation Project of CQ CSTC (cstc2018jcyjAX0751)
- Natural Science Foundation of Tianjin Municipal Science and Technology Commission (81661148057)
- Excellent Young Talents Fund Program of Higher Education Institutions of Anhui Province (CXTDX201601015)
- the Leading Talent Program of CQCSTC (CSTCCXLJRC201719)
This publication has 38 references indexed in Scilit:
- Low concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathwayInternational Journal of Oncology, 2013
- Cardiovascular, Ocular and Bone Adverse Reactions Associated with ThiazolidinedionesDrug Safety, 2012
- The AMPK signalling pathway coordinates cell growth, autophagy and metabolismNature Cell Biology, 2011
- Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patientsAnnals of Oncology, 2011
- Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individualsBMC Cancer, 2011
- Long-Term Metformin Use Is Associated With Decreased Risk of Breast CancerDiabetes Care, 2010
- Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitizationProceedings of the National Academy of Sciences, 2009
- p21 in cancer: intricate networks and multiple activitiesNature Reviews Cancer, 2009
- Activation of Peroxisome Proliferator-Activated Receptor γ (PPARγ) by Rosiglitazone Suppresses Components of the Insulin-Like Growth Factor Regulatory System in Vitro and in VivoEndocrinology, 2007
- Role of AMP-activated protein kinase in mechanism of metformin actionJournal of Clinical Investigation, 2001